已发表论文

肝脂肪变性分析与超声引导衰减参数在评估肝脂肪变性中的平台间一致性协议

 

Authors Chen J, Hao YH, Zhang YJ, Liu JJ, Liang P, Liu LP

Received 7 April 2025

Accepted for publication 2 July 2025

Published 15 July 2025 Volume 2025:18 Pages 4023—4032

DOI https://doi.org/10.2147/JMDH.S528289

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Pavani Rangachari

Juan Chen,1,2 Yan-Hong Hao,1 Yan-Jing Zhang,1 Jing-Jing Liu,1 Ping Liang,3 Li-Ping Liu1 

1Department of Interventional Ultrasound, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People’s Republic of China; 2Department of Ultrasonography, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, 030001, People’s Republic of China; 3Department of Interventional Ultrasound, Fifth Medical Center, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China

Correspondence: Li-Ping Liu, Department of Interventional Ultrasound, First Hospital of Shanxi Medical University, No. 85, Jiefang South Road, Taiyuan, 030001, People’s Republic of China, Tel +86 13623419190, Email liuliping1600@sina.com Ping Liang, Department of Interventional Ultrasound, Fifth Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, People’s Republic of China, Tel +86 13623419190, Email liangping301@hotmail.com

Objective: Liver steatosis analysis (LiSA) and the ultrasound-guided attenuation parameter (UGAP) are recently introduced commercially available techniques for the non-invasive evaluation of hepatic steatosis. This study aimed to assess the interplatform agreement between LiSA and UGAP in quantifying hepatic fat content.
Methods: Individuals diagnosed with or suspected of having fatty liver disease were included in the study. The overall interplatform agreement between LiSA and UGAP was assessed. The cohort was classified into 8 groups: 4 groups based on steatosis severity (S0-S3) and 4 groups based on predominant etiologies including non-alcoholic fatty liver disease, alcoholic liver disease, drug-induced fatty liver disease, and other causes. Paired-sample t-tests were used to compare LiSA and UGAP values. Interplatform agreement was evaluated using Bland‒Altman analysis with 95% limits of agreement (LOAs) and intraclass correlation coefficients (ICCs). The Pearson’s correlation coefficient was calculated to assess the relationship between LiSA and UGAP.
Results: A cohort of 357 patients with available LiSA, UGAP, and controlled attenuation parameter measurements were included in the study. No significant differences were observed between LiSA and UGAP values (p > 0.05). Pearson’s correlation coefficients ranged from ranged from 0.89 to 0.94 across all groups, while ICCs exceeded 0.80. Bland‒Altman analysis demonstrated slight biases between LiSA and UGAP, ranging from − 6.17 to 1.97 dB/m for all groups, with 95% LOAs for mean attenuation coefficient values ranging from − 40.55 to 36.09 dB/m.
Conclusion: LiSA and UGAP exhibited excellent interplatform agreement and can be used interchangeably for longitudinal monitoring of patients with hepatic steatosis.

Keywords: attenuation, fatty liver, interplatform, liver steatosis analysis, ultrasonography, ultrasound-guided attenuation parameter